AIRNA

About AIRNA

AIRNA is a biotech company dedicated to developing RNA editing therapeutics to transform the lives of patients with rare diseases and common conditions, aiming to deliver functional cures through innovative science and platforms.

Products & Services

RNA editing therapeutics for rare and common diseases, with potential to provide individual solutions at scale.

AIR-001, a product candidate for Alpha-1 Antitrypsin Deficiency, targeted for Phase 1/2 clinical trials.

Specialties

RNA editing Genetic medicines Therapeutics for rare and common conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 155000000 MR: - FA: $155 Million FAN: 155000000	D: 2025-04-01 FD: 2025-04-01	7 investors
2	RT: Series A T: - FT: Series A	A: 60000000 MR: - FA: $60 million FAN: 60000000	D: 2024-07-31 FD: 2024-07-31	5 investors

Series B Latest

2025-04-01

$155.0M

7 investors (Pro only)

Series A 2024-07-31

$60.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

V

Victor De Jesus

Associate Scientist

S

Sruthi V. Hindupur

Senior Scientist

R

Rodger Novak

Board Chair

R

Robert Altshuler

Director, Bioinformatics

N

Namita Bisaria

Head of Research Strategy and Operations

P

Peter Borsos

Research Associate

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

AIRNA Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised